GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE CONSULTANTS UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLANGlobal Non-Qualified Share Option Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations
Name of Optionee: _____________________________________ No. of Option Shares: ____________________ Ordinary Shares (as defined below) Option Exercise Price per Share: $___________________ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average closing price of the Company’s ADSs quoted on the NASDAQ for the five trading days immediately preceding date of grant] Grant Date: ____________________ Expiration Date: ____________________ [No more than 10 years]
GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR CONSULTANTS UNDER BEIGENE, LTD.Global Restricted Share Unit Award Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations
Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan as amended through the Grant Date (the “Plan”), and this Global Restricted share Unit Award Agreement for Consultants, including any additional terms and conditions for the Grantee’s country set forth in the appendix attached hereto (the “Appendix” and together with the Global Restricted Share Unit Award Agreement, the “Agreement”) BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability, (the “Company”) hereby grants an award of the number of Restricted Share Units listed above (an “Award”) to the Grantee named above. Each Restricted Share Unit shall relate to one ordinary share, par value US$0.0001 per share of the Company (the “Ordinary Shares”). The Ordinary Shares may be represented by American Depositary Shares (“ADSs”), and each ADS represents 13 Ordinary Shares. References herein to the issuance of Ordinary Shares shall also refer to the issuance of ADSs on the same basis of o
GLOBAL NON-QUALIFIED SHARE OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLANGlobal Non-Qualified Share Option Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations
Name of Optionee: _____________________________________ No. of Share Options: ____________________ Ordinary Shares (as defined below) Option Exercise Price per Share: $___________________ [Must be the higher of (a) 1/13 of the closing price of the Company’s ADSs as quoted on the NASDAQ on the date of grant, and (b) 1/13 of the average closing price of the Company’s ADSs quoted on the NASDAQ for the five trading days immediately preceding date of grant] Grant Date: ____________________ Expiration Date: ____________________ [No more than 10 years]
GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER BEIGENE, LTD. 2016 SHARE OPTION AND INCENTIVE PLANGlobal Restricted Share Unit Award Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations
Pursuant to the BeiGene, Ltd. 2016 Share Option and Incentive Plan, as amended through the Grant Date (the “Plan”), and this Global Restricted Share Unit Award Agreement for Non-Employee Directors, including any additional terms and conditions for the Grantee’s country set forth in the appendix attached hereto (the “Appendix,” and together with the Global Restricted Share Unit Award Agreement for Non-Employee Directors, the “Agreement”), BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), hereby grants an award of the number of Restricted Share Units listed above (an “Award”) to the Grantee named above, who is a Non-Employee Director. Each Restricted Share Unit shall relate to one ordinary share, par value US$0.0001 per share of the Company (the “Ordinary Shares”). The Ordinary Shares may be represented by American Depositary Shares (“ADSs”), and each ADS represents 13 Ordinary Shares. References herein to the issuance of Ordina
AMENDED AND RESTATED EMPLOYMENT APPORTIONMENT AGREEMENTEmployment Apportionment Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations • Beijing
This Amended and Restated Employment Apportionment Agreement (this “Agreement”) is made and entered into by and among BeiGene (Beijing) Co., Limited (the “Company”), BeiGene Guangzhou Biologics Manufacturing Co., Ltd. (the “GZ Co.”), BeiGene Pharmaceutical (Shanghai) Co., Ltd. (the “SH Co.”) and Dr. Wu Xiaobin (the “Executive”), on June 16, 2023 and effective as of June 1, 2023 (the “Effective Date”). Capitalized terms used but not defined in this Agreement shall have the meanings assigned to them in the Executive Employment Agreement entered into by and between the Company and the Executive, effective as of April 30, 2018 (the “Employment Agreement”).
ContractFacility Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations • Hong Kong
Important Note: Dear customers, in order to protect your rights and interests, please read the full content of this Agreement carefully before your execution, especially the articles in bold. In case of any doubt, please ask us for explanation in a timely manner. If there are still any doubts or ambiguities, please consult with your lawyers and relevant professionals.
MUTUAL TERMINATION AND RELEASE AGREEMENTMutual Termination and Release Agreement • August 2nd, 2023 • BeiGene, Ltd. • Pharmaceutical preparations • New York
This MUTUAL TERMINATION AND RELEASE AGREEMENT (this “Agreement”), dated as of July 10, 2023, is entered into by and between Novartis Pharma AG, a Swiss corporation (“Novartis”) and BeiGene Switzerland GmbH, a Swiss corporation (“BeiGene”). Each of Novartis and BeiGene may be referred to herein as a “Party” and collectively as the “Parties.”
